Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs

Davide Facchinelli, Gessica Marchesini, Gianpaolo Nadali, Livio Pagano, Davide Facchinelli, Gessica Marchesini, Gianpaolo Nadali, Livio Pagano

Abstract

This review summarizes the more recent evidence about epidemiology and risk factors for invasive fungal infections (IFI) in patients affected by Chronic Lymphocytic Leukemia (CLL), indolent Non Hodgkin Lymphoma (iNHL) and Multiple Myeloma (MM). Despite advances in the prognosis and treatment of hematological malignancies in recent years, susceptibility to infection remains a significant challenge to patient care. A large amount of data regarding patients with acute leukemia has been published while little information is available on the incidence of IFI in chronic lymphoproliferative disorders (CLD). New drugs are now available for treatment of lymphoproliferative disorders which may cause suppression of humoral immunity, cellular immunity, and deficiency of white blood cells, increasing the risk for infections which remain the leading cause of mortality in these patients.

Conflict of interest statement

Competing interests: The authors have declared that no competing interests exist.

References

    1. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573–81. doi: 10.1182/blood-2015-03-567388.
    1. Compagno N, et al. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626. doi: 10.3389/fimmu.2014.00626.
    1. Nosari AM, et al. Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience. Leuk Lymphoma. 2014;55(8):1844–8. doi: 10.3109/10428194.2013.853299.
    1. Pagano L, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31(2):17–29. doi: 10.1016/j.blre.2016.09.002.
    1. Pagano L, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.
    1. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53(8):798–806. doi: 10.1093/cid/cir492.
    1. Stanzani M, et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One. 2013;8(9):e75531. doi: 10.1371/journal.pone.0075531.
    1. Sun C, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–9. doi: 10.1182/blood-2015-04-639203.
    1. Teng JC, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100(11):e462–6. doi: 10.3324/haematol.2015.126698.
    1. Tisi MC, et al. Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. Haematologica. 2017;102(3):e108–e111. doi: 10.3324/haematol.2016.151837.
    1. Varughese T, et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies. Clin Infect Dis. 2018 doi: 10.1093/cid/ciy175.
    1. Visentin A, et al. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematol Oncol. 2017;35(4):925–928. doi: 10.1002/hon.2343.
    1. Williams AM, et al. Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma. 2018;59(3):625–632. doi: 10.1080/10428194.2017.1347931.
    1. Francis S, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107(5):1023–33. doi: 10.1002/cncr.22094.
    1. Sun Y, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumour Biol. 2015;36(2):757–67. doi: 10.1007/s13277-014-2649-7.
    1. Ruchlemer R, Ben Ami R, Lachish T. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(16):1593–4.
    1. Ghez D, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959. doi: 10.1182/blood-2017-11-818286.
    1. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240–9. doi: 10.1053/j.seminoncol.2005.12.013.
    1. Ravandi F, O’Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55(2):197–209. doi: 10.1007/s00262-005-0015-8.
    1. Moreira J, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27(1):136–41. doi: 10.1038/leu.2012.187.
    1. Morrison VA, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001;19(16):3611–21. doi: 10.1200/JCO.2001.19.16.3611.
    1. Hensel M, et al. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol. 2003;122(4):600–6. doi: 10.1046/j.1365-2141.2003.04497.x.
    1. Steinbach WJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65(5):453–64. doi: 10.1016/j.jinf.2012.08.003.
    1. Knauf WU, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378–84. doi: 10.1200/JCO.2008.20.8389.
    1. Fischer K, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209–16. doi: 10.1200/JCO.2011.39.2688.
    1. Fischer K, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559–66. doi: 10.1200/JCO.2010.33.8061.
    1. Anaissie EJ, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129(7):559–66. doi: 10.7326/0003-4819-129-7-199810010-00010.
    1. Wierda W, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4070–8. doi: 10.1200/JCO.2005.12.516.
    1. Keating MJ, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–88. doi: 10.1200/JCO.2005.12.051.
    1. Byrd JC, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood. 2003;101(1):6–14. doi: 10.1182/blood-2002-04-1258.
    1. Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. doi: 10.1056/NEJMoa1313984.
    1. Martin SI, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43(1):16–24. doi: 10.1086/504811.
    1. Elter T, et al. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol. 2009;88(2):121–32. doi: 10.1007/s00277-008-0566-9.
    1. Furman RR, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. doi: 10.1056/NEJMoa1315226.
    1. Sehn LH. Introduction to a review series: the paradox of indolent B-cell lymphoma. Blood. 2016;127(17):2045–6. doi: 10.1182/blood-2016-03-692442.
    1. Baden LR, et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(7):882–913. doi: 10.6004/jnccn.2016.0093.
    1. Ahn IE, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940–1943. doi: 10.1182/blood-2016-06-722991.
    1. Chamilos G, Lionakis MS, Kontoyiannis DP. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clin Infect Dis. 2018;66(1):140–148. doi: 10.1093/cid/cix687.
    1. Arthurs B, et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep. 2017;21:27–29.
    1. Baron M, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017;58(12):2981–2982. doi: 10.1080/10428194.2017.1320710.
    1. Lionakis MS, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017;31(6):833–843.e5.
    1. Choquet S, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107(8):3053–7. doi: 10.1182/blood-2005-01-0377.
    1. Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410–2418. doi: 10.1200/JCO.2017.72.7602.
    1. Tillman BF, et al. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100(4):325–334. doi: 10.1111/ejh.13020.
    1. Dubovsky JA, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–49. doi: 10.1182/blood-2013-06-507947.
    1. de Zwart L, et al. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacol Ther. 2016;100(5):548–557. doi: 10.1002/cpt.419.
    1. Stilgenbauer S, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018;36(19):1973–1980. doi: 10.1200/JCO.2017.76.6840.
    1. Takaoka K, et al. A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma. Ann Hematol. 2014;93(10):1637–44. doi: 10.1007/s00277-014-2093-1.
    1. Kurosawa M, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96(6):748–57. doi: 10.1007/s12185-012-1210-y.
    1. Jantunen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol. 2004;73(3):174–8. doi: 10.1111/j.1600-0609.2004.00273.x.
    1. Herbrecht R, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012;1272:23–30. doi: 10.1111/j.1749-6632.2012.06829.x.
    1. Montagna MT, et al. Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance. Int J Mol Sci. 2012;13(1):774–87. doi: 10.3390/ijms13010774.
    1. Dimopoulos MA, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241–250. doi: 10.1016/S1470-2045(16)30632-5.
    1. Klingspor L, et al. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre 2005–2009. Mycoses. 2015;58(8):470–7. doi: 10.1111/myc.12344.
    1. Pagano L, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95(4):644–50. doi: 10.3324/haematol.2009.012054.
    1. Nosari AM, et al. Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. Clin Microbiol Infect. 2013;19(8):757–62. doi: 10.1111/1469-0691.12014.
    1. Fleming S, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1283–97. doi: 10.1111/imj.12595.
    1. Pagano L, et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl 1):i5–14. doi: 10.1093/jac/dkq437.
    1. Gil L, et al. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant. 2009;43(2):121–6. doi: 10.1038/bmt.2008.303.
    1. Vazquez L, et al. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. Rev Esp Quimioter. 2017;30(2):103–117.
    1. van Hal SJ, et al. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand. Intern Med J. 2014;44(12b):1277–82. doi: 10.1111/imj.12594.
    1. Mellinghoff SC, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) Ann Hematol. 2018;97(2):197–207. doi: 10.1007/s00277-017-3196-2.
    1. Reinwald M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors) Clin Microbiol Infect. 2018;24(Suppl 2):S53–S70. doi: 10.1016/j.cmi.2018.02.009.
    1. Wang ML, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45. doi: 10.1182/blood-2015-03-635326.
    1. Teh BW, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28–31. doi: 10.3324/haematol.2014.114025.
    1. Huang BH, et al. [The clinical features and risk factors for invasive fungal infection in multiple myeloma]. Zhonghua Nei Ke Za Zhi. 2009;48(12):1026–30.
    1. Cornet M, et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect. 2002;51(4):288–96. doi: 10.1053/jhin.2002.1258.
    1. Lortholary O, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network 2005–2007. Clin Microbiol Infect. 2011;17(12):1882–9. doi: 10.1111/j.1469-0691.2011.03548.x.
    1. Liu J, et al. Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China. Tumour Biol. 2016;37(6):7893–900. doi: 10.1007/s13277-015-4441-8.
    1. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211–25. doi: 10.1086/605664.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel